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Abstract
Background: Human outbreaks of Ebola virus (EBOV) are a serious human health concern in Central Africa. Great apes (gorillas/
chimpanzees) are an important source of EBOV transmission to humans due to increased hunting of wildlife including the
‘bush-meat’ trade. Cytomegalovirus (CMV) is an highly immunogenic virus that has shown recent utility as a vaccine platform.
CMV-based vaccines also have the unique potential to re-infect and disseminate through target populations regardless of prior
CMV immunity, which may be ideal for achieving high vaccine coverage in inaccessible populations such as great apes.
Methodology/Principal Findings: We hypothesize that a vaccine strategy using CMV-based vectors expressing EBOV
antigens may be ideally suited for use in inaccessible wildlife populations. To establish a ‘proof-of-concept’ for CMV-based
vaccines against EBOV, we constructed a mouse CMV (MCMV) vector expressing a CD8+ T cell epitope from the
nucleoprotein (NP) of Zaire ebolavirus (ZEBOV) (MCMV/ZEBOV-NPCTL). MCMV/ZEBOV-NPCTL induced high levels of long-
lasting (.8 months) CD8+ T cells against ZEBOV NP in mice. Importantly, all vaccinated animals were protected against
lethal ZEBOV challenge. Low levels of anti-ZEBOV antibodies were only sporadically detected in vaccinated animals prior to
ZEBOV challenge suggesting a role, at least in part, for T cells in protection.
Conclusions/Significance: This study demonstrates the ability of a CMV-based vaccine approach to protect against an
highly virulent human pathogen, and supports the potential for ‘disseminating’ CMV-based EBOV vaccines to prevent EBOV
transmission in wildlife populations.
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Introduction
Ebola virus (EBOV), a member of the Filoviridae family, causes
rapidly progressing viral hemorrhagic fever culminating in multi-
organ failure, shock and death [1]. EBOV can be subdivided into
four distinct and a fifth putative species [2,3]. EBOV species differ in
level of virulence, with Zaire ebolavirus (ZEBOV) being the most
virulent (80–90% case fatality) [4]. The unpredictable nature of
EBOV outbreaks in endemic areas of Africa, combined with the
potential for accidental and deliberate introduction into non-
endemic nations ensures that EBOVwill most likely remain a global
health concern well into the future. Potential for rapid dissemination
to non-endemic countries was demonstrated in 2008 by importation
of Marburg virus (a filovirus closely related to EBOV) to the US [5]
and Netherlands [6] by tourists infected in Uganda.
Animal species involved in EBOV transmission to humans are
not completely defined [7]. Asymptomatically infected fruit bats
have been identified during EBOV outbreaks, suggesting that bats
may be a reservoir [8]. EBOV infection is also observed in great
apes (chimpanzees/gorillas), where it is highly pathogenic with a
similar disease course to humans [9–11]. Handling and butchering
of EBOV-infected wildlife and carcasses including great apes is an
important mode of transmission to humans [7,9,12,13]. In the
eighteen outbreaks of EBOV in Africa since its discovery in 1976,
three were associated with exposure to environments inhabited by
bats, and seven resulted from contact with great ape carcasses (the
source of the remaining outbreaks was not established) [3,7].
Although EBOV was identified in fruit bats in the EBOV
outbreaks of 2001 and 2003, all known transmissions to humans
resulted from handling great ape carcasses [9]. Due to its high
pathogenicity in great apes, EBOV infection is also regarded as a
major threat to the survival of great ape species in the wild [9–11].
Given the threat by EBOV for the extinction of great apes and
the role of great apes in EBOV transmission to humans,
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vaccination of these animals in the wild has been proposed to save
these endangered wildlife species and to reduce the incidence of
human EBOV outbreaks [7,14]. A number of candidate EBOV
vaccines have been developed that are protective against infection
in animal models [15,16]. Replication-defective adenovirus (Ad)
expressing EBOV glycoprotein (GP) alone [17] or in combination
with nucleoprotein (NP) [18], virus-like particles comprised of
virus matrix protein (VP40) and GP with or without NP [19,20],
and replication-competent human parainfluenza virus type 3
(HPIV3) [21], and vesicular stomatitis virus (VSV) expressing GP
[22,23] are all able to consistently induce protective immunity in
small animal and non-human primate (NHP) models. Oral
immunization with the VSV-based vaccine has been shown to
induce protection in mice and NHPs [24,25], leading to the
suggestion of its use for food baiting [7,14]. However, all of these
EBOV vaccine approaches induce immunity only in the
vaccinated individual as they are unable to disseminate through
the population.
A ‘disseminating’ cytomegalovirus (CMV)-based vaccine offers
an alternative approach whereby high coverage would be achieved
by vaccine spread from initial vaccinees through the target
population by animal-to-animal contact. CMV is an ubiquitous,
but benign b-herpesvirus that establishes life-long, latent/low level
persistent infection within the host [26]. During latent infection
the virus is believed to be maintained as an extrachromosomal
chromatin-complexed episome [27]. After initial infection, CMV
is shed from epithelial surfaces into body fluids (saliva, urine,
genital secretions and breast milk), and transmission generally
involves mucosal exposure to such fluids, most commonly in early
childhood or adolescence [28,29]. CMV possesses the remarkable
ability to reinfect and establish a persistent infection regardless of
host CMV immunity [30–33]. CMV is also one of the most
immunogenic viruses known [34], inducing a characteristic
immune response that is highly enriched for ‘effector’ memory
(TEM) T cells [33]. TEM cell localization is shifted toward non-
lymphoid, mucosal sites, and TEM cells are functionally primed for
immediate anti-pathogen effector function [35]. Due to this high
immunogenicity, interest in developing CMV as a vaccine vector is
increasing [36–38]. The recent capacity to manipulate the CMV
genome using bacterial artificial chromosome (BAC)-based
technology has facilitated development of CMV as a vaccine
vector [39]. To date, target antigens have been expressed in CMV
either as single T cell epitopes fused to a non-essential CMV gene
[36], or as single full-length proteins under the control of
heterologous promoters [33,40]. CMVs are host-specific, with
each mammalian host being infected with its own distinct CMV
[41,42]. The high efficacy of CMV-based vaccines was recently
demonstrated by the ability of a panel of rhesus CMV (RhCMV)-
based vectors each expressing a distinct simian immunodeficiency
virus (SIV) antigen to prevent systemic SIV infection of rhesus
macaques (a NHP model for HIV), which is the first vaccine to
prevent acquisition of fully pathogenic SIV [33,43].
Our long-term goal is to develop a ‘disseminating’ vaccine
against EBOV based on chimpanzee/gorilla-specific CMV vectors
that will prevent EBOV infection in gorillas and chimpanzees. We
hypothesize that protection of these animals from EBOV will
interfere with the transmission of EBOV from these species to
humans. In the present report we have constructed a mouse CMV
(MCMV)-based EBOV vector expressing a single CTL epitope
from NP of ZEBOV (MCMV/ZEBOV-NPCTL) as a prototype
vector to establish ‘proof-of-concept’ for this approach. MCMV/
ZEBOV-NPCTL was shown to be highly immunogenic, inducing
durable CD8+ CTL responses (IFNc+/TNFa+) against ZEBOV
NP in multiple strains of mice. Importantly, MCMV/ZEBOV-
NPCTL conferred protection against lethal challenge with a mouse-
adapted ZEBOV variant. The general absence of antibodies
against ZEBOV in protected animals prior to ZEBOV challenge,
and lack of protection in controls receiving wild-type (WT) ‘empty’
MCMV vector were consistent with protection being, at least in
part, T cell-mediated. This is the first study to demonstrate the
ability of a CMV-based vaccine to protect against an human
pathogen, and supports the concept of ‘disseminating’ CMV-based
EBOV vaccines to prevent EBOV transmission in wild animal
populations.
Materials and Methods
Ethics statement
All animal use complied with the Guide for the Use and Care of
Laboratory Animals, USDA Animal Welfare Regulations, PHS
Policy on Humane Care and Use of Laboratory Animals and
other relevant regulations. All procedures were approved by the
respective IACUC committees at Rocky Mountain Laboratories,
Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health (RML, DIR,
NIAID, NIH), and Oregon Health and Science University
(OHSU).
Construction and characterization of MCMV vectors
MCMV-based vectors were constructed by lambda-phage
based linear recombination using a strategy identical to that used
for construction of other CMV recombinants [33]. MCMV (Smith
strain) BAC pSMfr3 [44,45] in which the natural killer (NK) cell
activating m157 MCMV gene has been deleted (pSMfr3Dm157)
was used as the genetic background for these vectors. Deletion of
m157 was necessary to avoid attenuation of CMV replication by
inadvertent high NK cell control in the C57BL/6 mouse strain
that expresses the corresponding Ly49H NK receptor [46]. For
construction of MCMV/ZEBOV-NPCTL an H2
b-restricted T cell
epitope from NP of ZEBOV (43-VYQVNNLEEIC-54) [47,48]
was fused ‘in-frame’ to the carboxyl terminus of MCMV IE2 (ie2)
generating the recombinant MCMV BAC, pMCMV/ZEBOV-
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Great apes (gorillas/chimpanzees) are an important source
of EBOV transmission to humans. Candidate EBOV vaccines
do not spread from the initial vaccinee. In addition to
being highly immunogenic, vaccines based on the
cytomegalovirus (CMV) platform have the unique potential
to re-infect and disseminate through target populations.
To explore the utility of CMV-based vaccines against EBOV,
we constructed a mouse CMV (MCMV) vector expressing a
region of nucleoprotein (NP) of Zaire ebolavirus (ZEBOV)
(MCMV/ZEBOV-NPCTL). MCMV/ZEBOV-NPCTL induced high
levels of long-lasting CD8+ T cells against ZEBOV NP in
mice. Importantly, all vaccinated animals were protected
against lethal ZEBOV challenge. The absence of ZEBOV
neutralizing and only low, sporadic levels of total anti-
ZEBOV IgG antibodies in protected animals prior to ZEBOV
challenge indicate a role, albeit perhaps not exclusive, for
CD8+ T cells in mediating protection. This study demon-
strates the ability of a CMV-based vaccine approach to
protect against ZEBOV, and provides a ‘proof-of-concept’
for the potential for a ‘disseminating’ CMV-based EBOV
vaccine to prevent EBOV transmission in wild animal
populations.
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NPCTL. IE2 is a nonessential MCMV protein to which we and
others have fused defined T cell epitopes as a strategy for induction
of T cell responses following infection of mice with the
corresponding recombinant MCMV [36]. A contiguous frt-flanked
kanamycin resistance marker (KanR) was inserted into the MCMV
BAC genome at the same time as the NP epitope to enable
selection of recombinant BACs on the basis of kanamycin
resistance. Following selection of recombinant BACs on the basis
of KanR, the frt-flanked KanR marker was removed by arabinose
induction of Flp-recombinase and screening for kanamycin
sensitivity. Virus was reconstituted from BACs by transfection
into murine embryo fibroblasts (MEFs). Presence of the BAC
cassette within the MCMV genome decreases in vivo replication,
and serial in vitro passage of the BAC-derived virus was performed
to remove the BAC cassette [45]. Absence of the BAC cassette
from reconstituted MCMV vectors was confirmed by PCR using
BAC cassette-specific primers. MCMV/ZEBOV-NPCTL viruses
were assessed for growth in vitro on MEFs. To avoid effects of
inadvertent second site mutations, two independently derived
MCMV/ZEBOV-NPCTL clones (5A1 and 5D1) were selected,
and growth was compared to WT MCMV (MCMVDm157). For
assessment of virus growth kinetics, cells were infected at a
multiplicity of infection (MOI) of 0.1 and media was harvested for
quantitation of virus at increasing times post-infection by standard
plaque assay. DNA sequencing of BAC and reconstituted viral
DNA was used to confirm integrity of the NP epitope within the
MCMV genome.
Animal models, vaccination and challenge
Mice were purchased from NCI at Frederick, MD. All
experiments were performed with age-matched female 129S1/
SvlmJ/Cr and C57BL/6 mice. Mice were provided food and
water ad libitum. For analysis of the kinetics of the peripheral blood
anti-NP T cell response, mice received a single intraperitoneal
(i.p.) inoculum of MCMV/ZEBOV-NPCTL (1610
5 pfu), and were
then bled over a 33 week period at times indicated. In all other
cases, MCMV-vaccinated mice were inoculated i.p. with
56105 pfu of MCMV recombinants followed by an identical i.p.
‘boost’ after 4 weeks. After 10 weeks, C57BL/6 mice were
challenged i.p. with 103 LD50 of mouse-adapted ZEBOV (ma-
ZEBOV) as previously described [24]. For these studies, VSVDG/
ZEBOVGP (given as a single i.p. dose of 56105 pfu) served as a
positive control for vaccine protection. The VSVDG/ZEBOVGP
is a recombinant VSV, in which the native glycoprotein G has
been exchanged for GP ZEBOV (Mayinga strain), and has been
shown to induce protective immunity against ma-ZEBOV [24].
Following challenge, disease severity was monitored on the basis of
clinical signs using an approved scoring index, and mortality rate
was recorded over the 28 day post-challenge period. ZEBOV in
vivo replication was also directly determined by quantification of
ma-ZEBOV viremia levels at time of peak viremia in mice (day 4
post-challenge) by virus titration using a focus forming unit
immunodetection assay with titre expressed as focus forming units
(FFU/ml). All BSL-4 level infectious work was performed at RML.
Intracellular cytokine staining analysis of T cells
Frequencies of CD8+ T cells directed against the ZEBOV NP
CTL epitope, or MCMV-encoded M38 and M45 proteins in
pooled peripheral blood or spleen were determined by intracel-
lular cytokine staining (ICS). Cells were stimulated in the presence
of brefeldin A (BFA) (10 mg/ml) with peptides representing defined
H2b-restricted epitopes of ZEBOV NP (VYQVNNLEEIC) [47],
MCMV M38 (SSPPMFRV) or M45 (HGIRNASFI) [49], or
prostate-specific antigen (PSA) (HCIRNKSVI) [50]. PSA was used
as an irrelevant antigen control, and the peptides representing the
well-characterized H2b-restricted epitopes in MCMV-encoded
M45 and/or M38 [49] served as an indicator of MCMV vector
infection. Incubation without antigen served as a background
control. After 6 hours of stimulation, cells were stained using the
following monoclonal antibodies (Mabs) in designated combina-
tions: a) from BD Biosciences, RM4-5 (CD4; Pacific Blue), 53-6.7
(CD8a; PerCP-Cy5.5), MP6-XT22 (TNFa; PE), XMG1.2 (IFNc;
APC), and b) from eBioscience 17A2 (CD3e, APC-eFluor780).
After surface and intracellular staining with conjugated Mabs,
polychromatic flow cytometric analysis was performed on a LSR
II (BD Biosciences), and data was analyzed by using FlowJo
software (version 9.1; Tree Star, Inc.). Samples were performed in
triplicate. Response frequencies were determined by subtracting
background and then averaging background subtracted responses.
Neutralization assay
Sera was collected from vaccinated mice at times indicated, and
analyzed for ability to neutralize ZEBOV infection in an in vitro
neutralization assay [51]. Briefly, heat inactivated sera (56uC for
45 minutes) was serially diluted in DMEM, and then mixed 1:1
with ZEBOV expressing the EGFP reporter (ZEBOV-EGFP)
(200 FFU/well). After incubation at 37uC for 60 minutes, 20 ml of
the mixture was transferred onto subconfluent Vero cells in a 96-
well plate format and incubated for 30 minute at 37uC. Following
addition of 180 ml of DMEM supplemented with 1.5% carbox-
ymethyl cellulose and 5% FBS, cells were cultured for 4 days at
37uC. Cells were washed by PBS and fixed in 10% neutral
buffered formalin overnight under BSL-4 conditions. Prior to
removal from the BSL-4 conditions, formalin was changed and
plates were processed under BSL-2 conditions by conventional
methods. Values shown are the sera dilutions resulting in 50%
reduction in EGFP-positive cells following infection of Vero cells
with ZEBOV-EGFP. Mab#226 is a neutralizing mouse mono-
clonal antibody made against ZEBOV GP [52].
Virus-like particle (VLP)-based enzyme-linked
immunosorbent assay (ELISA)
Total IgG antibody responses to ZEBOV NP, GP and VP40
were quantified by ELISA using ZEBOV VLPs (VP40/NP/GP) as
an antigen source [25]. Generation of VLPs has been previously
described [53]. Briefly, 96 well microtiter plates (NUNC,
Rochester, NY) were coated with ZEBOV VLPs (2 mg/ml) in
PBS at 4uC overnight, and then blocked with 5% skim milk in PBS
containing 0.05% Tween 20 (PBST) for 2 hours at room
temperature. After three washes with PBST, 50 ml of diluted
heat-inactivated serum sample was added and the plates were
incubated for 1 hour at 37uC. After an additional three washes
with PBST, secondary antibody conjugated with horseradish
peroxidase (HRP) was added and plates were incubated for an
additional 1 hour at 37uC. Bound antibodies were quantified using
the ABTS Peroxidase Substrate System (KPL, Gaithersburg, MD)
by measuring absorbance at 405 nm on a microplate spectropho-
tometer. Values shown are the end-point dilution titre (using a 4-
fold dilution series). Samples were deemed positive when the value
was higher than the mean plus 4 standard deviations of negative
(Mock) mouse sera [25].
Statistical analysis
Statistical analyses were performed using GraphPad version
5.0 d for Mac OS X, GraphPad Software, San Diego CA, USA,
www.graphpad.com. An unpaired Student’s two-tailed t-test was used
to compare treatment groups. A Kaplan-Meier estimator and a
CMV-Based Vaccine Protects against Ebola Virus
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log-rank test were used to compare survival rates between
treatment groups in ma-ZEBOV challenge studies.
Results and Discussion
To assess the potential of CMV for development as a vaccine
against EBOV, we designed a prototype murine cytomegalovirus
(MCMV)-based EBOV vaccine (MCMV/ZEBOV-NPCTL) ex-
pressing a CD8+ CTL epitope from ZEBOV NP (43-VYQVNN-
LEEIC-53; NP43) [47,48,54] fused to a non-essential MCMV
protein, IE2 (Figure 1a). MCMV/ZEBOV-NPCTL was construct-
ed by lambda-based linear recombination using a BAC containing
the MCMV genome (pSM3fr) [33,45]. Independent pMCMV/
ZEBOV-NPCTL clones (5A1 and 5D1) were selected for
characterization. Restriction enzyme digestion followed by
electrophoresis showed no gross genomic rearrangements com-
pared to WT parental BAC (Figure S1). Viruses were reconstituted
by transfection of BAC DNA into MEFs. In vitro growth analysis of
reconstituted viruses showed replication kinetics comparable to
WT MCMV (Figure S2).
CMV induces high levels of T cells against both endogenous
and heterologously expressed proteins [33,34,36]. To assess the
level of NP-specific CD8+ CTL responses induced by MCMV/
ZEBOV-NPCTL, we performed immunogenicity studies in H2
b-
restricted 129S1/SvlmJ/Cr mice. Mice (n = 5/group) were
immunized intraperitoneally (56105 pfu; i.p.) with MCMV/
ZEBOV-NPCTL (clone 5A1 or 5D1), MCMV/PSA (clone 3-1),
WT MCMV or diluent (Mock). MCMV/PSA (clone 3-1) is a
Figure 1. T cell responses following immunization with MCMV/ZEBOV-NPCTL. (a) Schematic representation of MCMV/ZEBOV-NPCTL. An H2
b-
restricted T cell epitope from ZEBOV NP (VYQVNNLEEIC) was fused ‘in-frame’ to the carboxyl terminus of MCMV IE2 (ie2) generating the recombinant
MCMV, MCMV/ZEBOV-NPCTL. MCMV IE2 is a non-essential protein. (b) 129S1/SvlmJ/Cr (H2
b-restricted) mice (n = 5/group) were immunized i.p. using
56105 pfu of the following: one of two independent clones of MCMV/ZEBOV-NPCTL (5A1 and 5D1), MCMV/PSA (clone 3-1) (a comparable MCMV
vector expressing IE2 fused to an H2b-restricted epitope from PSA), WT MCMV, or diluent (Mock control). Mice were boosted after 4 weeks. After 8
weeks splenocytes were harvested for analysis of T cell responses. T cells were analyzed by using ICS with a 6 hour incubation in the presence of BFA
with peptide (or anti-CD3 Mab, for total T cell response). Levels of responding (IFNc and TNFa double-positives) CD8+ (top) and CD4+ (bottom) cells in
individual mice are shown. All MCMV/ZEBOV-NPCTL immunized mice (n = 10) showed significant CD8-restricted T cell responses against the NP target
antigen. (c) Typical responses from MCMV/ZEBOV-NPCTL vaccinated mice. The majority of ZEBOV NP-responding T cells expressed both IFNc and
TNFa and are specific for the NP epitope (not observed following incubation with the PSA peptide or unstimulated controls). Consistent with MCMV
infection, all mice demonstrate T cell responses to MCMV M45. T cell responses directed against M45 are known to be ‘non-inflationary’, generally
representing ,1% of total CD8+ T cells during chronic MCMV infection. Error bars show the standard deviation (s.d.).
doi:10.1371/journal.pntd.0001275.g001
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control MCMV expressing an irrelevant H2b-restricted epitope
from PSA [50]. After 4 weeks, mice were ‘boosted’ using an
identical inoculum. After 8 weeks, splenocytes were harvested for
analysis of T cell responses (Figure 1b). Antigen-specific T cells
were analyzed by ICS following a 6 hour in vitro incubation with
EBOV and MCMV peptides representing different H2b-restricted
epitopes. All MCMV/ZEBOV-NPCTL vaccinated mice exhibited
significant CD8+ CTL responses against ZEBOV NP (Figure 1b).
The level of NP responses elicited by 5A1 and 5D1 were not
significantly different, and were considered together as a single
data set. The ZEBOV NP-specific T cell responses induced were
substantial (mean=2.83% of total CD8+ T cells; range= 0.32 to
5.99%), CD8+ phenotype (no response in CD4+ cell compart-
ment), and specific (directed against ZEBOV NP, but not PSA
control). CD8+ CTLs induced against ZEBOV NP primarily
expressed both IFNc and TNFa effector cytokines (Figure 1c). All
mice except mock-vaccinated controls had CD8+ CTLs directed
against the MCMV-encoded M45 protein.
A unique characteristic of CMV-induced immune responses is
their ‘inflation’ over time with maturation into stable ‘effector’ T
cell (TEM) memory that persists for life [55]. Compared to classical
‘central’ memory (TCM) cells, TEM are biased toward localization
at mucosal epithelial effector sites, and have more immediate
effector function [56,57]. To determine the durability of ZEBOV
NP-specific T cell responses from a single MCMV/ZEBOV-
NPCTL inoculation, mice (n = 14) were vaccinated (1610
5 pfu; i.p.)
with MCMV/ZEBOV-NPCTL, and peripheral T cell responses
were followed longitudinally. NP-specific CD8+ T cell responses
gradually accumulated to high levels and persisted (increasing
from 0.79% after 8 weeks, to 3.08% after 33 weeks following the
single inoculation) (Figure 2). Although delayed, the NP-specific
CTL response was comparable in kinetics of induction and
magnitude to the TEM-biased ‘inflationary’ response directed
against MCMV M38 [49,58]. Importantly, these results show that
a CMV-based EBOV vaccine can induce high levels of CD8+ T
cells against an EBOV antigen that increase with time and are
durable.
To determine whether MCMV/ZEBOV-NPCTL was able to
induce protective immunity against lethal ZEBOV challenge, we
performed challenge studies in C57BL/6 mice using ma-ZEBOV
[24,59]. The ma-ZEBOV is lethal in unvaccinated mice, which
succumb 5–7 days post-challenge [24,59]. Four groups of mice
(n = 20/group) were immunized (56105 pfu; i.p.) with MCMV/
ZEBOV-NPCTL 5A1 or 5D1, MCMV WT or diluent, and
Figure 2. Kinetic analysis of CD8+ T cell response to MCMV/ZEBOV-NPCTL. 129S1/SvlmJ/Cr H2
b-restricted mice (n = 14) were immunized (i.p.)
with a single dose (16105 pfu) of MCMV/ZEBOV-NPCTL (clone 5D1). At times indicated, mice were bled and peripheral T cell responses were measured
in pooled blood by using ICS with a 6 hour incubation in the presence of BFA with peptides. All responses were normalized against cells stimulated in
the absence of peptide. Responses are against ZEBOV NP (black), or MCMV M38 (grey) and M45 (white). Error bars show the s.d.
doi:10.1371/journal.pntd.0001275.g002
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boosted after 4 weeks (Figure 3). After 8 weeks (4 weeks following
the boost), splenocytes from 6 mice/group were analyzed for T cell
responses. 5A1 and 5D1 induced comparable responses against
NP, enabling mice receiving either clone to be considered as a
single data set. MCMV/ZEBOV-NPCTL induced considerable
levels of CD8+ T cells against ZEBOV NP (mean= 1.34% of total
CD8+ T cells; range = 0.05 to 2.68%). These results also show that
the ability of MCMV/ZEBOV-NPCTL to induce NP-specific T
cells is independent of the mouse strain (Figures 1b and 3). All
mice except mock-vaccinated controls had CD8+ CTLs directed
against MCMV-encoded M38 and M45.
After 10 weeks (6 weeks following the boost), the remaining mice
(n = 14/group) were challenged i.p. with 103 LD50 of ma-ZEBOV.
An additional group (n = 14) that had received VSVDG/
ZEBOVGP (56105 pfu; i.p.), which confers high levels of
protection against ma-ZEBOV, was included as a control for
vaccine protection [24]. ZEBOV disease was then monitored on
the basis of survival, morbidity based on clinical signs (ruffled fur,
hunched posture, paralysis and weight loss) and viremia. Mock
and MCMV WT vaccinated controls exhibited ZEBOV disease
and significant morbidity (Figure 4b) with 90% of mice
succumbing between days 5–7 post-challenge (Figure 4a). In
contrast, MCMV/ZEBOV-NPCTL vaccinated mice showed no
evidence of ZEBOV disease, with 100% survival and no signs of
morbidity (Figures 4a and 4b). As a quantitative analysis of vaccine
efficacy, viremia at day 4 post-challenge (peak of ZEBOV viremia
in the mouse model) was measured in a subset of mice (n = 3–4/
group) harvested at this time (Figure 4c). MCMV/ZEBOV-
NPCTL vaccination resulted in a significant level of control of
ZEBOV replication. Specifically, 5 of 8 mice showed no detectable
levels of viremia; the remaining 3 mice showed a 2.8-log reduction
in viremia compared to WT MCMV vaccinated controls. Given
the expression of a single CTL epitope from NP it was highly
unlikely that anti-ZEBOV antibodies (either neutralizing or total)
would be induced by vaccination. However, it was possible that a
low-level of ZEBOV replication in vaccinated animals would
result in induction of anti-ZEBOV antibodies. To investigate the
possibility that neutralizing antibodies induced by the challenge
virus were positively impacting protection, we waited a sufficient
period of time (28 days) for any antibodies induced by challenge to
have risen to detectable levels. At 28 days post-challenge ma-
ZEBOV neutralizing activity in sera from a randomly selected
subset (n = 6) of protected MCMV/ZEBOV-NPCTL mice was
measured. VSVDG/ZEBOVGP control mice had low, but
detectable levels of neutralizing activity following challenge as
previously observed [24]. In contrast, neutralizing activity was not
Figure 3. MCMV/ZEBOV-NPCTL induces a ZEBOV-specific T cell response in C57BL/6 mice. C57BL/6 H2
b-restricted mice (n = 6/group) were
vaccinated (i.p.) using 56105 pfu of MCMV/ZEBOV-NPCTL clone 5A1 or 5D1. Control groups received either MCMV WT, or diluent (Mock). After 4
weeks mice were boosted as before. After 8 weeks (4 weeks post-boost) mice were harvested for analysis of splenocyte T cell responses by ICS using
a 6 hour incubation in the presence of BFA with indicated peptide. MCMV-specific CD8+ T-cell responses against MCMV M45 and M38 were used as
markers of MCMV infection. PSA peptide served as an H2b-restricted epitope specificity control. Responding CD8+ cells shown are IFNc and TNFa
double-positives. Mice groups presented in this figure were vaccinated in parallel with mice groups (n = 14/group) used to ascertain protective
efficacy of vaccination regimen shown in Figure 4. Error bars show the s.d.
doi:10.1371/journal.pntd.0001275.g003
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detected in any convalescent serum from MCMV/ZEBOV-
NPCTL vaccinated mice demonstrating that the role of neutralizing
antibodies in mediating protection in these mice was minimal
(Table S1).
Vaccination of either NHPs [22] or mice [24] with VSVDG/
ZEBOVGP is known to induce a total IgG anti-ZEBOV response
(presumably directed against ZEBOV GP). Although VSVDG/
ZEBOVGP confers a level of protection that results in the
complete lack of detectable ZEBOV viremia [22], the anti-
ZEBOV antibody response induced by VSVDG/ZEBOVGP is
subsequently boosted by ZEBOV challenge. An antibody-capture
ELISA (using VLPs comprised of VP40, NP and GP as a source of
antigen) [53] was used to measure levels of total anti-ZEBOV IgG
antibodies in MCMV/ZEBOV-NPCTL vaccinated mice, both
prior to challenge and at day 28 post-challenge (Table S2).
Consistent with expression of the single NP CTL epitope, anti-
ZEBOV antibodies were not detected, or present sporadically at
only low levels (in one of three mice tested) in MCMV/ZEBOV-
NPCTL vaccinated mice prior to ma-ZEBOV challenge. In
contrast, convalescent sera from protected mice in this treatment
group had high levels of total IgG directed against ZEBOV (at 28
days post-challenge). VSVDG/ZEBOVGP-vaccinated mice re-
sponded as previously described with anti-ZEBOV IgG antibodies
being induced by vaccination, which were then boosted by ma-
ZEBOV challenge (Table S2). Whether the anti-ZEBOV antibody
response in either of these treatment groups is induced by active
ZEBOV replication or represents exposure to the initial antigen
bolus received at the time of challenge is unclear. The relatively
greater anti-ZEBOV IgG response observed in MCMV/ZEBOV-
NPCTL compared to VSVDG/ZEBOVGP vaccinated mice
following challenge may indicate an higher level of ongoing
ZEBOV replication in the MCMV/ZEBOV-NPCTL vaccinated
mice following challenge. The absence of neutralizing antibodies
and barely detectable and sporadic levels of total IgG against
ZEBOV in MCMV/ZEBOV-NPCTL vaccinated mice prior to
ma-ZEBOV challenge suggests that NP-specific CTL, and not
antibodies, are playing a greater role in protection. These results
do not exclude other mechanisms being involved in protection,
such as neutralizing or non-neutralizing antibodies below the level
of detection in our assay, as well as non-specific innate responses
induced by the CMV vector itself. Although the inability of WT
MCMV to afford any level of protection would presumably
suggest minor involvement of non-adaptive, innate responses. De
novo ZEBOV-specific CTL responses directed against ZEBOV-
encoded antigens other than NP induced by the challenge virus
can also not be excluded.
Great apes are an important source of EBOV transmission to
humans [7,8,9,12,13]. Vaccination campaigns for rabies in
European and US wildlife [60] have shown the effectiveness of
targeting animal species involved in transmission. Vaccination of
great apes to interrupt EBOV transmission may therefore be an
effective strategy to decrease human EBOV outbreaks. In the
current study, we demonstrate that a prototype CMV-based
vaccine expressing a single CTL NP epitope can induce a
considerable level of protection against ZEBOV. The present
study therefore establishes a ‘proof-of-concept’ for a CMV-based
EBOV vaccine in the C57BL/6 mouse challenge model prior to
moving forward with more complex CMV-based vectors (species-
specific) expressing full-length EBOV proteins in more robust
Figure 4. Protective efficacy of MCMV/ZEBOV-NPCTL. Groups of
C57BL/6 mice (n = 14) were vaccinated by i.p. administration of
56105 pfu of either MCMV/ZEBOV-NPCTL (clones 5A1 or 5D1), MCMV
WT, or diluent (Mock), followed by an identical boost at week 4. An
additional group received VSVDG/ZEBOVGP as a positive control for
vaccine efficacy. After 10 weeks (6 weeks after the boost), mice were
challenged with 103 LD50 ma-ZEBOV (i.p.). Data represent (a) Percent
survival. (b) Body weight change over time post-challenge (error bars
show the s.d.). (c) Viremia levels in 3–4 mice harvested at time of peak
viremia (day 4) (mean viremia levels for each group are shown in
parentheses). For body weight, groups were weighed daily until 14 days
post-EBOV challenge, or until all animals in a group had succumb to
ZEBOV disease. MCMV/ZEBOV-NPCTL vaccination had a significant
impact on survival from ma-ZEBOV challenge compared to MCMV WT
controls (p,0.0001) using a log-rank test. Analysis of ma-ZEBOV viremia
shows a comparable level in control of viremia between 5A1 and 5D1
MCMV/ZEBOV-NPCTL vaccinated groups, compared to MCMV WT
controls (p,0.0001).
doi:10.1371/journal.pntd.0001275.g004
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NHP challenge models. Given the outbred nature of primates with
their expression of a diverse repertoire of MHC I alleles, a final
CMV based vaccine will assuredly need to encode single or
perhaps multiple full-length EBOV proteins.
In addition to being highly immunogenic, CMV has evolved a
remarkable ability to spread between individuals, and therefore
may be suited for development as a ‘disseminating’ vaccine
platform to target geographically inaccessible wild animal
populations like great apes at relatively low cost. In this strategy,
vaccination of ‘founder vaccine recipients’ would be used to
initiate spread of the CMV-based EBOV vaccine through animal
populations eliminating the need for immunization of each
individual. An important characteristic of CMV that makes this
vector ideally suited to development as a ‘disseminating’ vaccine is
its remarkable ability to reinfect and establish a persistent infection
regardless of host CMV immunity [29,31,32,61]. Recent studies in
rhesus macaques show that immunogenicity and capacity to re-
infect the CMV immune host is relatively independent of CMV
dose, as inoculums as low as 100 pfu of rhesus CMV (RhCMV)
were able to reinfect and induce immunity in RhCMV sero-
positive animals [62]. As CMV is transmitted through breast milk
from mothers to offspring, a CMV-based vaccine could also afford
a more permanent solution to the EBOV problem. Although
vertical transmission of superantigens encoded by endogenous
mammary tumour viruses (MMTV) can cause clonal deletion of
reactive T cell subsets [63], vertical transmission of CMV appears
to be distinctly different to MMTV, with mature and functional
human CMV specific T cells being consistently observed in
congenitally infected neonates (and one aborted foetus of 28 weeks
gestation) [64,65].
There are clearly some potential risks associated with use of
such a ‘disseminating’ vaccine approach targeting wildlife
populations. However, in addition to the impact of EBOV on
human health, EBOV is regarded as a major threat to survival of
great apes [11]. With potential for achieving high levels of
coverage in inaccessible and environmentally harsh regions, a
‘disseminating’ CMV-based EBOV approach may not only
benefit humans, but may also positively impact survival of these
great ape species in the wild. Concerns regarding the possible
environmental impact of releasing a recombinant vaccine vector
that can spread within the target population, especially a
population that is endangered, cannot be overstated. However
a number of additional characteristics of this vaccine approach
help to allay these concerns. First, CMV has been shown to be
ubiquitous within its respective host population in all NHP
species studied [66–69]. Therefore, a CMV-based vaccine for use
in great ape species represents infection with a benign virus
(either gorilla or chimpanzee CMV) that is already present within
the population, differing only by expression of EBOV antigens.
Second, CMVs are believed to be highly host-specific with each
mammalian host studied carrying its own species-specific CMV
[70]. This host-specificity is recapitulated to a certain level in vitro,
with only CMVs from closely related species being able to
replicate in cells from other closely related species. For example,
human CMV (HCMV) was able to replicate, but at a 10-fold
lower level, in primary chimpanzee compared to human
fibroblasts [71]. However, HCMV is unable to replicate in
mouse fibroblasts [72], and MCMV is reciprocally unable to
replicate or is severely compromised for replication in human
fibroblasts [72,73]. For rodent CMVs, the block in cross-species
infection has been shown to be due to an inability to control
apoptosis following infection of the cross-species cell type [73].
The responsible mechanism for species restriction in primate
CMVs is not known.
CMV is ubiquitous in all NHP species studied (baboons, drill
monkeys and rhesus macaques) [66–68]. A chimpanzee CMV
strain (CCMV, Panine herpesvirus 2) has been isolated from a
chimpanzee in captivity and the genome fully sequenced. The
CCMV genome was largely co-linear with that of HCMV, but
with a moderate level of divergence [74]. Leendertz et al [75] have
subsequently detected multiple additional CMV species in samples
from captive and wild gorillas (Western Lowland), chimpanzees
(West and East African), as well as orangutans using a degenerate
PCR-based assay targeting conserved genes. Together with
HCMV, as well as the earlier isolated CCMV and old world
and new world monkey CMVs, Leendertz et al [75] separated
primate CMVs into six major clades on the basis of partial
sequence of a conserved essential protein, gB. HCMV strains
localized within their own clade (93–95% amino acid identity),
whilst gorilla and chimpanzee CMVs were contained within two
clades [CG1 clade: CCMV, Pan troglodytes CMV genogroup 1, and
Gorilla gorilla CMV genogroup 1 (76–77% amino acid identity with
HCMV gB); and CG2 clade: Pan troglodytes CMV genogroup 2,
and Gorilla gorilla CMV genogroup 2 (81–82% amino acid identity
with HCMV gB) [75]. Consistent with earlier studies, most of the
primate CMVs were found only in their respective host species
with which they had co-evolved. However, the presence of
chimpanzee and gorilla CMVs together within the same clade
raises the possibility of horizontal bi-directional transmission of
CMV between chimpanzees and gorillas. CMV detection was
based solely on the presence of subgenomic fragments of viral
DNA within tissue samples by PCR and not isolation of infectious
virus. However, any possibility for transmission between closely
related primate species clearly indicates a need for empirical
studies to confirm the high species-specificity of CMV between
closely related primate species.
In summary, using the mouse ma-ZEBOV challenge model, we
have established ‘proof-of-concept’ for CMV as a potential
‘disseminating’ vaccine for EBOV. Future and ongoing studies
are focused on the design of CMV vectors expressing full-length
EBOV proteins, as well as assessment of efficacy in the NHP
model using RhCMV-based vectors. The high immunogenicity,
combined with the ability of CMV to spread regardless of prior
CMV immunity and host-specificity, make ‘disseminating’ CMV-
based vaccines a novel vaccine platform that may be ideal for
targeting EBOV, as well as other pathogens, in animal populations
that are inaccessible due to geography or vaccination cost.
Supporting Information
Figure S1 Genomic characterization of MCMV/ZEBOV-
NPCTL. BAC DNA from two independent clones of MCMV/
ZEBOV-NPCTL (5A1 and 5D1) were digested with EcoRI
followed by electrophoresis. The comparable digest pattern
between MCMV/ZEBOV-NPCTL BAC clones and the MCMV
WT BAC shows the lack of any gross genomic rearrangement.
(EPS)
Figure S2 Multi-step growth analysis of MCMV/ZEBOV-
NPCTL. MEFs were infected at a MOI of 0.1 with either 5A1,
5D1 or WT MCMV. Supernatant was collected at days indicated
post-infection and titered by standard plaque assay. The assay was
performed in triplicate and standard deviation is shown.
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